Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

All Drugs and Chemicals

Immunomodulating Agents

Immunologic Factors

Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.

This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.

CAR-T cell immunotherapy

Lizhi Niu, PhD

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients.

Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at EphA2 antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safty and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients.

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma

Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, magnetic resonance imaging, and/or positron emission tomography images.

After CAR-T cell infusion,we will detect the persistence of CAR-T cells by flow-cytometric analysis.And we will observe if this CAR T cells can significantly inhibite the tumor growth by discovering the change of tumor volume.

After CAR-T cell infusion,we will observe the potential adverse events related to the T-cell infusion such as high fever,jaundice, kidney failure and so on.

Fuda Cancer Hospital, Guangzhou

Respiratory Tract (Lung and Bronchial) Diseases

Digestive System Diseases

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Squamous Cell

Adenocarcinoma

Stomach Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Small Cell Lung Carcinoma

Carcinoma, Transitional Cell

Squamous Cell Carcinoma of Head and Neck

Sarcoma

Endometrial Neoplasms

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neoplasms, Squamous Cell

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Connective and Soft Tissue

Head and Neck Neoplasms

Uterine Neoplasms

Uterine Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Small Cell Lung Cancer

Transitional Cell Carcinoma

Soft Tissue Sarcoma

Antineoplastic Agents

Gemcitabine

Carboplatin

MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.

MM-310

Vasileios Askoxylakis, MD, PhD

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.

A Study Evaluating MM-310 in Patients With Solid Tumors

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Merrimack Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients	NCT02575261	EphA2 Positive ... CAR-T Cell Immu...	CAR-T cell immu...	18 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
A Study Evaluating MM-310 in Patients With Solid Tumors	NCT03076372	Solid Tumors Urothelial Carc... Gastric Carcino... Squamous Cell C... Ovarian Cancer Pancreatic Duct... Prostate Adenoc... Non-small Cell ... Small Cell Lung... Triple Negative... Endometrial Car... Soft Tissue Sar...	MM-310	18 Years -	Merrimack Pharmaceuticals
A Study Evaluating MM-310 in Patients With Solid Tumors	NCT03076372	Solid Tumors Urothelial Carc... Gastric Carcino... Squamous Cell C... Ovarian Cancer Pancreatic Duct... Prostate Adenoc... Non-small Cell ... Small Cell Lung... Triple Negative... Endometrial Car... Soft Tissue Sar...	MM-310	18 Years -	Merrimack Pharmaceuticals

Spots Global Cancer Trial Database for epha2

Every month we try and update this database with for epha2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for epha2

Every month we try and update this database with for epha2 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for epha2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.